

UNAUDITED FINANCIAL RESULTS (PROVISIONAL)

	FOR THE QUARTER ENDED	30TH JUNE, 2013		RS in A	MILCION -
S. No.	PARTICULARS	Quarter Ended of			
4		30/06/2013 Unaudited	31/03/2013	30/06/2012 Unaudited	31/03/2013 Audited
1	Part – I	Offaudited	Onadanca	Onductou	
1	Net Sales/ Income from operations	1268.79	1253.11	1123.75	4,602.58
	Gross Sales	2.34		3.41	11.61
	Less : Excise Duty	1266.45		1120.34	4,590 97
	(a) Net Sales	5.63		5.38	22 41
	(b) Other Operating Income			1,125.72	4,613.38
	Total Income from Operation (Net)	1,272.08	1,253.17	1,125.72	4,010.00
2	Expenses	750.50	705.00	050.07	2,725 58
	(a) Consumption of raw materials	752 50			-92 93
	(b) (Increase)/ Decrease in stock in trade	-2,80			
	(c) Employee benefits expense	59:17			232 38
	(d) Depreciation & amortization expense	95.35			317.62
	(e) Other expenses	147.14			563.47
	Total expense	1,051.36			3,746.12
3	Profit from operations before other income, finance costs	220.72	220.70	219.51	867.26
	and exceptional items (1-2)				
4	Other income	8.18	-3.45		3_95
5	Profit before finance costs and exceptional items (3+4)	228.90	217.25	220.77	871.21
6	Finance Costs	66.81	61.68		244 49
7	Profit after finance costs but before exceptional items (5-6	162.09	155.57	144.62	626.72
8	Exceptional items	0.00	0	0.00	00.00
9	Profit from ordinary activities before tax (7+8)	162.09	155.57	144.62	626.72
10	Tax expense	8.97	36.04	4.17	55.27
11	Profit from ordinary activities after tax (9-10)	153.12	119.53	140.45	571.45
12	Exceptional items (net of tax expense	00.00	0.00	00.00	0.00
13	Net profit for the period (11-12)	153.12	119.53	140.45	571.45
14	Paid up Equity Share Capital	114.42	105.42	97.42	105.42
15	Reserves excluding revaluation reserves	N. A		N. A.	3,769.22
16	E.P.S - Basic not annualised for the qtr	13.38		14.42	54.2
	- Annualised	53.53			54.2
	Part – II (A)				
1	Public Shareholding				
3	- Number of Shares	6437086	6437086	6388986	6437086
	- Percentage of Shareholding	56.26			61.06
2	Promoters and promoter group shareholding	00,20	, , , , ,		
	a) Pledged as collateral security to bank				
12	- Number of Shares	1930000	1930000	1930000	1930000
13	- Percentage of shares (as a % of the total share	38 56			
	holding of promoter and promoter group	50 50	77 02.	. 3, 30	77 02
in in	- 1	16.0	7 18.31	19.81	18,31
31	- Percentage of shares (as a % of the total share capital	16.87	10.31	13.01	10,5
10	b) Non-Encumbered	2074004	2474000	1423002	2174902
10	- Number of Shares	3074902			
12	- Percentage of shares (as a % of the total share	61.44	52.98	42.44	52,98
13	holding of promoter and promoter group	1			
14	- Percentage of shares (as a % of the total share capital	26.87	7 20.63	14.61	20.63
46	Particulars 3 months ended				

NIL

NIL

FOR VENUS REMEDIES LIMITED

Pending at the beginning of the quarter

Remaining unresolved at the end of the quarter

Received during the quarter
Disposed of during the quarter



Notes:

- 1. The above Un-audited (Provisional) financial Results for the period ended 30.06.2013 were reviewed by the Audit Committee and taken on record at the board Meeting on August 3, 2013.
- 2. During the Quarter:
- a) The Company has made it to the list of Top 100 in the "India's Best Companies to Work for" study conducted by the Great Place to Work Institute, India in association with The Economic Times Placed at the 72nd position.

b) The Company has received Mexico patent for its research product 'POTENTOX'.

c) The Company has been awarded Gold Medal by DST_Lockheed Martin India Innovation growth program - 2013 for its research product 'ELORES'.

d) The Company out -licensed Elores a novel antibiotic adjuvant entity for South Korea after patent grant.

- 3. The Statutory Auditors have carried out Limited Review of the above Un- audited financial results in terms of Clause 41 of the listing Agreement.
- 4. During the Quarter, one investor grievance was received and resolved. No other investor grievance was pending at the end of the quarter.
- 5. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED

Place: Panchkula Date: 03.08.13

Chairman & Managing Director



J. K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS

S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 60

0172-270 4536-37 Fax: 0172-270 E-mail: jkjcaps@rediffmail

Snjoy Innovations

REVIEW REPORT

The Board of Directors, Venus Remedies Limited 51-52, Industrial Area, Phase-I Panchkula

We have reviewed the accompanying statement of un-audited Financial Results of Venus Remedies Limited for the Quarter ended 30.06.2013. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagements to Review financial statements' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited Quarterly financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for J. K. Jain & Associates,

(Chartered Accountants

V P ANDIGAR

Partner M.Ne. 089760

Date: 03.08.2013 Place: Chandigarh

CERTIFIED TO BE TRUE COPY

For Venus Remedies Limited

(Company Secretary)